Slingshot members are tracking this event:

FDA approves Gilead Sciences (GILD) Vosevi for the treatment of HCV genotypes 1 through 6

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
GILD Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 18, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Vosevi, Hcv, Genotype 1-6, Fda Approval